Lixivaptan
As of the edition of 20 October 2026, Lixivaptan is a small molecule: stopped in 2022; acts on AVPR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 11, 4 stopped early
- Disease areas
- Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Nutrition and metabolism; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Lixivaptan.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AVPR2 | Vasopressin V2 receptor | P30518 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 7 | 3 | 0 | 4 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Critical Therapeutics | Lead sponsor of trials | 2007 to now |
| Palladio Biosciences | Lead sponsor of trials | 2020 to now |